Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

被引：64

作者：

Natelson, EA ^{[1
]}

Giovanella, BC ^{[1
]}

Verschraegen, CF ^{[1
]}

Fehir, KM ^{[1
]}

DeIpolyi, PD ^{[1
]}

Harris, N ^{[1
]}

Stehlin, JS ^{[1
]}

机构：

[1] ST JOSEPH HOSP, STEHLIN FDN CANC RES, HOUSTON, TX 77003 USA

来源：

CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT | 1996年 / 803卷

关键词：

D O I：

10.1111/j.1749-6632.1996.tb26392.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：224 / 230

页数：7

共 14 条

[1] GIOVANELLA BC, 1991, CANCER RES, V51, P3052
[2] GOTTLIEB JA, 1972, CANCER CHEMOTH REP 1, V56, P103
[3] GOVINDACHARI T R, 1972, Phytochemistry (Oxford), V11, P3529, DOI 10.1016/S0031-9422(00)89852-0
[4] MODIFICATION OF THE HYDROXY LACTONE RING OF CAMPTOTHECIN - INHIBITION OF MAMMALIAN TOPOISOMERASE-I AND BIOLOGICAL-ACTIVITY
HERTZBERG, RP
CARANFA, MJ
HOLDEN, KG
JAKAS, DR
GALLAGHER, G
MATTERN, MR
MONG, SM
BARTUS, JO
JOHNSON, RK
KINGSBURY, WD
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (03) : 715 - 720
[5] HINZ HR, 1994, CANCER RES, V54, P3096
[6] MARKED INTERSPECIES VARIATIONS CONCERNING THE INTERACTIONS OF CAMPTOTHECIN WITH SERUM ALBUMINS - A FREQUENCY-DOMAIN FLUORESCENCE SPECTROSCOPIC STUDY
MI, ZH
BURKE, TG
[J]. BIOCHEMISTRY, 1994, 33 (42) : 12540 - 12545
[7] PANTAZIS P, 1994, EUR J HAEMATOL, V53, P246
[8] PANTAZIS P, 1995, CANCER J - FRANCE, V8, P119
[9] POTMESIL M, 1994, CANCER RES, V54, P1431
[10] RUBIN E, 1995, CLIN CANCER RES, V1, P269